 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
| «123 |
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Enrollment closed: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 15, 2015
P3, N=467, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting
- |||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Trial primary completion date: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA (clinicaltrials.gov) - Aug 26, 2014
P3, N=350, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Jul 2014
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Enrollment closed: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2014
P3, N=526, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2015 --> Jul 2014 Recruiting --> Active, not recruiting
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Trial initiation date: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - May 1, 2014
P3, N=425, Ongoing, Sponsor: Amgen Inc.
Recruiting --> Active, not recruiting Initiation date: Feb 2014 --> Feb 2014
- ||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
Enrollment closed: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA (clinicaltrials.gov) - Apr 15, 2014
P3, N=350, Active, not recruiting, Sponsor: Amgen
Initiation date: Feb 2014 --> Feb 2014 Recruiting --> Active, not recruiting
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P3 trial: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 13, 2014
P3, N=425, Ongoing, Sponsor: Amgen Inc.
- |||||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P3 trial: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA (clinicaltrials.gov) - Oct 24, 2013
P3, N=350, Active, not recruiting, Sponsor: Amgen
- |||||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
New P3 trial: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 24, 2013
P3, N=500, Recruiting, Sponsor: Amgen